Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: J Thorac Oncol. 2018 Nov 29;14(3):482–493. doi: 10.1016/j.jtho.2018.11.017

Fig 2.

Fig 2.

Lung cancer–specific cumulative incidence of death (LC-CID) and overall survival for patients with and without major pathologic response (MPR; ≤10% viable tumor). (A) MPR was associated with significantly better LC-CID (P=0.001). (B) MPR was associated with significantly better overall survival (P=0.041). VT, viable tumor.